Compassionate use of sorafenib in patients with advanced renal cell cancer

Clinical Genitourinary Cancer

Volumn 7, Issue 1, 2009, Pages 34-38

  Laber, Damian A ^a,b   Mushtaq, Mian ^a  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

C met pathway inhibitors; Leukopenia; Neutropenia; Non clear cell carcinoma

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; METHOTREXATE; SORAFENIB; TEMOZOLOMIDE; THALIDOMIDE; VINBLASTINE; WARFARIN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLOOD CLOTTING DISORDER; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MALE; METASTASIS; NAUSEA; PRACTICE GUIDELINE; RADIATION DOSE; RASH; RISK BENEFIT ANALYSIS; STOMATITIS; THROMBOCYTOPENIA; THRUSH; KIDNEY TUMOR; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PAPILLARY CARCINOMA; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 65249179019     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.006     Document Type: Article

References (13)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin 2008; 58:71-96.
2. Laber DA. Risk factors, classification and staging of renal cell cancer. Med Oncol 2006; 24:443-454.
3. (Pubitemid 40545819) Cohen D, Zhou M, Cohen D, et al. Molecular genetics of familial renal cell carcinoma syndromes. Clin Lab Med 2005; 25:259-77.
4. (Pubitemid 40826133) Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92:1855-61.
5. (Pubitemid 41510145) Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16:1688-94.
6. (Pubitemid 46202316) Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-72.
7. (Pubitemid 46630627) Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505-12.
8. (Pubitemid 46089673) Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Eng J Med 2007; 356:125-34.
9. (Pubitemid 30099779) Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [see comment]. J Natl Cancer Inst 2000; 92:205-16.
10. Knox JJ, Figlin RA, Stadler WM, et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J Clin Oncol 2007: 25 (18 suppl) 237s (Abstract 5011).
11. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute, 2003. Available at: http://ctep. cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed: December 31, 2008.
12. Nexavar (sorafenib) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2008. Available at: http://berlex. bayerhealthcare.com/html/products/pi/Nexavar-PI.pdf. Accessed: December 31, 2008.
13. Data on File. Bayer Pharmaceuticals. NDA 15.6 (8.4.2.8.1).